Almac, Pfizer, PETACC 3 Launch Colorectal Cancer Gene-Expression Study

The trio plan to use Almac's Colorectal Cancer Disease-Specific Array in a retrospective study of formalin-fixed, paraffin-embedded samples. The goal is to uncover subgroups and drug targets in colorectal cancer "that may inform therapeutic development in the future."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.